Table 2.
Bevacizumab, Efficacy, and Toxicity
| Study | Best HR (Response/ Testable) | Best HD (Response/ Testable) | Best RR (Response/ Testable) | Best PD (Response/ Testable) | Toxicity (Grade 3 or 4 AE) |
|---|---|---|---|---|---|
| Morris et al. 201611 | 45% (5/11) | 6% (2/33) | 32% (15/47) | 17% (8/47) | Proteinuria (2%), hypertension (2%), psychosis (2%), anemia (2%), depression (2%), infections (2%), raised alanine aminotransferase (2%) |
| Blakeley et al. 20168 | 36% (5/14) | 0% (0/14) | 43% (6/14) | 0% (0/14) | Hypertension (14%), idiopathic thrombocytopenia purpura (7%) |
| Plotkin et al. 20199 | 41% (9/22) | 9% (2/22) | 32% (7/22) | 0% (0/22) | Hypertension (25%), abdominal pain (12.5%) |
| Alanin et al. 201417 | 33% (3/9) | 22% (2/9) | 50% (6/12) | 8% (1/12) | 1 death due to subarachnoid hematoma (8%) |
| Plotkin et al. 201210 | 57% (13/23) | 15% (4/26) | 55% (17/31) | 10% (3/31) | Hypertension (3%), menorrhagia (6%), irregular menstruation (6%), neutropenia (3%), vascular access complication (3%) |
| Farsctschi et al. 201518 | 0% (0/3) | 0% (0/3) | 100% (3/3) | 0% (0/3) | NR |
| Goutagny et al. 201619 | NR | NR | 36% (8/22) * | 9% (2/22) * | NR |
| Hochart et al. 201412 | 25% (1/4) | NR | 14% (1/7) | NR | Hypertension (14%), osteitis (14%) |
| Sverak et al. 201920 | 56% (5/9) | 11% (1/9) | 47% (8/17) | 6% (1/17) | Hypertension and proteinuria were most common |
| Renzi et al. 201913 | 62% (8/13) ** | NR | 12% (2/17) | NR | None |
| Pooled data (95% CI) |
(49/108) 45% (36–54) |
(11/116) 10% (4–15) |
(73/192) 38% (32–45) |
(15/168) 9% (5–13) |
*Target tumor not defined; result based on 22 tumors in 16 patients.
**Response based on results from audiogram.
Abbreviations: HR, hearing response; HD, hearing decline; RR, Radiological response; PD, progressive disease; AE, Adverse event; NR, not reported; CI, Confidence interval.